TAIPEI, Taiwan, July 21 /Xinhua-PRNewswire/ -- ScinoPharm Taiwan Ltd., a developer and producer of active pharmaceutical ingredients (APIs) that conform to international GMP standards, was awarded the 2005 Entrepreneurial Company Award by Frost & Sullivan in recognition of its outstanding entrepreneurial achievements. This award affirms ScinoPharm Taiwan’s creative process R&D, clientele development, entrepreneurial business strategies and overall cost-effectiveness. The award also signifies that ScinoPharm Taiwan is heading toward great success.
Frost & Sullivan was founded in New York in 1961. It is the world’s largest technology consultant company providing business strategies and market forecasts in production technology to assist investors to have a clear understanding of the trends and the challenges in these areas as well as helping the industry analyze new production technology to facilitate business growth. The Entrepreneurial Company Award will be presented to ScinoPharm Taiwan at the Biotechnology Industry Conference on July 21, 2005 at the Taipei Grand Hyatt Hotel.
According to Dr. Jo Shen, President and CEO of ScinoPharm Taiwan, the company will continue to insist and expect its employees to comply with the stringent requirements of international pharmaceutical regulations. It will also endeavor to implement the best international enterprise management concepts. ScinoPharm aims to establish excellent relationships with the local community, academic institutes, and peer-pharmaceutical companies. Today’s award by Frost & Sullivan evidences that ScinoPharm Taiwan has positioned itself well among the important members of the world’s leading pharmaceutical enterprises.
ScinoPharm Taiwan reported a US17.1 million in total sales in 2004. Compared to 2003, this represents an increase of over 100%. In 2005, the accumulated revenues for the first 6 months amounted to US$15.3 million which represented a 78.08% increase over the same period of the previous year. In February 2005 alone, revenue received topped US$2.9 million which registers the highest revenue ever recorded in ScinoPharm Taiwan’s seven year history. With the launching of APIs in Europe and the U.S., the company’s marketing department predicts sales in the next few years to grow exponentially.
At present, among ScinoPharm Taiwan’s major customers are many of the world’s top pharmaceutical firms. Aside from the production of generic APIs, the company also offers cooperative R&D and process manufacturing contract services. It has completed registration of 17 DMF in the U.S. and 22 countries such as Germany, England, France, Canada, New Zealand and Australia. This is tantamount to obtaining “admission tickets” into the European and the U.S. markets. ScinoPharm Taiwan’s APIs have been listed in the ANDA of customers as the chief and/or sole supplier, thus guaranteeing its future sales. Today, ScinoPharm Taiwan has 30 APIs and will continue to develop 10 new APIs every year.
Contact: ScinoPharm Taiwan, Ltd. http://www.scinopharm.com Maggie Lin Tel: +886-6505-2888 Email: magie.lin@scinopharm.com.tw
Taiwan Ltd.
ScinoPharm
CONTACT: Maggie Lin of ScinoPharm Taiwan, Ltd., +886-6505-2888,magie.lin@scinopharm.com.tw
Web site: http://www.scinopharm.com/
